Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

269P - Treatment for vasomotor symptoms in women on adjuvant endocrine therapy after breast cancer: real-world findings from the REALISE study

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Mia Harvey

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101224-101224. 10.1016/esmoop/esmoop101224

Authors

M. Scott1, M. Harvey1, N. Schoof2, S. Su Saydam2, C. Caetano3, C. Janssenswillen3, C. Moeller2, V.L. Banks4

Author affiliations

  • 1 Adelphi Real World - Adelphi Group, Bollington/GB
  • 2 Bayer AG, Berlin/DE
  • 3 Bayer Consumer Care AG, Basel/CH
  • 4 Bayer Plc, Reading/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 269P

Background

Women commonly experience menopausal symptoms including vasomotor symptoms (VMS) e.g. hot flashes whilst on adjuvant endocrine therapy (AET) after breast cancer. VMS treatment options are limited in this population. The REAL-world evIdence on vasomotor and other Symptoms in menopausal womEn (REALISE) study aimed to evaluate VMS treatment status and symptom burden in women taking AET after breast cancer.

Methods

The 2020 Adelphi VMS Disease Specific Programme™, a large, cross-sectional survey-based dataset was conducted between February - October in France, Germany, Italy, Spain, the United States, and United Kingdom. Oncologists (n=77) provided demographic, clinical, and treatment status data on adult women in breast cancer remission taking AET and experiencing VMS; patients were then asked to complete a voluntary self-report form including symptoms and the Menopause-Specific Quality of Life tool. Patients were stratified into treated (currently receiving VMS treatment) and untreated (never received treatment) groups. Analyses were descriptive.

Results

Of the 183 women providing self-report data (mean age 54.1 years [SD 9.9]; mean age at onset of induced menopause 48.8 years [SD 10.0]; 84.7% white), 54.1% were treated (69.7% with SSRI/SNRI), with median treatment duration of 34.8 weeks (IQR 26.1, 52.1); and 40.4% were untreated. Patients reported HF (92.2%), sweating (67.6%), difficulty sleeping (64.8%), anergia (56.4%), and mood symptoms (55.9%) most commonly over the prior week. Reporting of HF (treated: 95.8%; untreated: 89.2%), difficulty sleeping (65.6%; 63.5%), and mood symptoms (60.4%; 48.7%) was consistent regardless of treatment status. Patients in both groups reported moderate to severe bother of HF (treated: 47.9%; untreated: 27.4%), mood symptoms (22.9%; 24.3%), and sleep difficulties (25.3%; 27.4%, respectively).

Conclusions

Women in breast cancer remission receiving AET experienced a high VMS and concomitant symptom burden, yet 40.4% were not receiving treatment. Patients reported feelings of bother in relation to their VMS, mood and sleep over the last week regardless of treatment status, showing a need for new more effective treatment options for this underserved group.

Editorial acknowledgement

Editorial assistance was provided by Highfield Communication Consultancy, Oxford, UK.

Legal entity responsible for the study

Bayer AG.

Funding

Bayer AG.

Disclosure

M. Scott, M. Harvey: Financial Interests, Personal, Full or part-time Employment: Adelphi Real World. N. Schoof, S. Su Saydam, C. Moeller: Financial Interests, Personal, Full or part-time Employment: Bayer AG. C. Caetano, C. Janssenswillen: Financial Interests, Personal, Full or part-time Employment: Bayer Consumer Care. V.L. Banks: Financial Interests, Personal, Full or part-time Employment: Bayer UK.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.